Last reviewed · How we verify
Morphine-Naloxone
At a glance
| Generic name | Morphine-Naloxone |
|---|---|
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Vomiting
- Nausea
- Abdominal distension
- Pyrexia
- Anaemia
- Fatigue
- Urinary tract infection
- Neoplasm malignant
- Bone marrow failure
- Dizziness
- Upper respiratory tract infection
- Abdominal pain
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Clinical Decision Support to Improve System Naloxone Co-prescribing
- Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms (NA)
- Assessing a Clinically-meaningful Opioid Withdrawal Phenotype (PHASE2)
- Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain (PHASE4)
- Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2). (PHASE1)
- Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) (PHASE1)
- Evaluation of Oral PF614 Relative to OxyContin (PF614-102) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Morphine-Naloxone CI brief — competitive landscape report
- Morphine-Naloxone updates RSS · CI watch RSS
- Assiut University portfolio CI